PRAX vs. ICPT, SAGE, CMPS, TVTX, MGNX, XENE, CORT, FOLD, IDYA, and PTCT
Should you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Intercept Pharmaceuticals (ICPT), Sage Therapeutics (SAGE), COMPASS Pathways (CMPS), Travere Therapeutics (TVTX), MacroGenics (MGNX), Xenon Pharmaceuticals (XENE), Corcept Therapeutics (CORT), Amicus Therapeutics (FOLD), IDEAYA Biosciences (IDYA), and PTC Therapeutics (PTCT). These companies are all part of the "medical" sector.
Praxis Precision Medicines (NASDAQ:PRAX) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, community ranking, media sentiment, institutional ownership and profitability.
Praxis Precision Medicines has a beta of 2.87, indicating that its share price is 187% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.
Intercept Pharmaceuticals has a net margin of -19.39% compared to Praxis Precision Medicines' net margin of -5,711.85%. Intercept Pharmaceuticals' return on equity of -77.48% beat Praxis Precision Medicines' return on equity.
In the previous week, Praxis Precision Medicines had 1 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 2 mentions for Praxis Precision Medicines and 1 mentions for Intercept Pharmaceuticals. Praxis Precision Medicines' average media sentiment score of 0.87 beat Intercept Pharmaceuticals' score of 0.30 indicating that Praxis Precision Medicines is being referred to more favorably in the media.
Intercept Pharmaceuticals received 1040 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. Likewise, 72.32% of users gave Intercept Pharmaceuticals an outperform vote while only 63.41% of users gave Praxis Precision Medicines an outperform vote.
Intercept Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
Praxis Precision Medicines currently has a consensus target price of $105.80, suggesting a potential upside of 129.40%. Intercept Pharmaceuticals has a consensus target price of $19.00, suggesting a potential upside of 0.00%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Intercept Pharmaceuticals.
67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 83.8% of Intercept Pharmaceuticals shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 6.2% of Intercept Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Intercept Pharmaceuticals beats Praxis Precision Medicines on 10 of the 18 factors compared between the two stocks.
Get Praxis Precision Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Praxis Precision Medicines Competitors List
Related Companies and Tools
